Mark A. Klausner

1.8k total citations
24 papers, 1.2k citations indexed

About

Mark A. Klausner is a scholar working on Nephrology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark A. Klausner has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Nephrology, 7 papers in Hematology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark A. Klausner's work include Parathyroid Disorders and Treatments (7 papers), Erythropoietin and Anemia Treatment (5 papers) and Antifungal resistance and susceptibility (3 papers). Mark A. Klausner is often cited by papers focused on Parathyroid Disorders and Treatments (7 papers), Erythropoietin and Anemia Treatment (5 papers) and Antifungal resistance and susceptibility (3 papers). Mark A. Klausner collaborates with scholars based in United States, Canada and Singapore. Mark A. Klausner's co-authors include Thomas J. Weber, Jeffrey S. Humphrey, Karl Insogna, Munro Peacock, Erik A. Imel, Mary D. Ruppe, Addison K. May, Timothy C. Fabian, Ronald G. Pearl and Peter Bowers and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Blood.

In The Last Decade

Mark A. Klausner

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Klausner United States 14 446 315 191 187 164 24 1.2k
Barbara G. Delano United States 15 770 1.7× 650 2.1× 61 0.3× 52 0.3× 83 0.5× 40 1.5k
Benaya Rozen‐Zvi Israel 20 522 1.2× 507 1.6× 198 1.0× 81 0.4× 40 0.2× 81 2.1k
W. Kline Bolton United States 16 381 0.9× 272 0.9× 97 0.5× 45 0.2× 22 0.1× 23 1.1k
Neil Boyce Australia 29 1.2k 2.7× 105 0.3× 457 2.4× 61 0.3× 66 0.4× 81 2.3k
Peter Rogiers Belgium 22 317 0.7× 149 0.5× 462 2.4× 36 0.2× 131 0.8× 43 1.6k
Carlos A. Vaamonde United States 20 520 1.2× 212 0.7× 135 0.7× 53 0.3× 17 0.1× 68 1.4k
Dierik Verbeelen Belgium 19 297 0.7× 117 0.4× 151 0.8× 48 0.3× 16 0.1× 63 1.2k
Sun-Hee Park South Korea 23 869 1.9× 87 0.3× 124 0.6× 117 0.6× 15 0.1× 120 1.6k
M. Elli Italy 18 187 0.4× 48 0.2× 151 0.8× 68 0.4× 63 0.4× 66 1.1k
Ko‐Lin Kuo Taiwan 21 818 1.8× 303 1.0× 109 0.6× 45 0.2× 15 0.1× 69 1.9k

Countries citing papers authored by Mark A. Klausner

Since Specialization
Citations

This map shows the geographic impact of Mark A. Klausner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Klausner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Klausner more than expected).

Fields of papers citing papers by Mark A. Klausner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Klausner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Klausner. The network helps show where Mark A. Klausner may publish in the future.

Co-authorship network of co-authors of Mark A. Klausner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Klausner. A scholar is included among the top collaborators of Mark A. Klausner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Klausner. Mark A. Klausner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xiaoping, Erik A. Imel, Mary D. Ruppe, et al.. (2016). Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia. Publisher. 1 indexed citations
2.
Ruppe, Mary D., Xiaoping Zhang, Erik A. Imel, et al.. (2016). Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Reports. 5. 158–162. 44 indexed citations
3.
Imel, Erik A., Xiaoping Zhang, Mary D. Ruppe, et al.. (2015). Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal of Clinical Endocrinology & Metabolism. 100(7). 2565–2573. 114 indexed citations
4.
Zhang, Xiaoping, Erik A. Imel, Mary D. Ruppe, et al.. (2015). Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia. The Journal of Clinical Pharmacology. 56(2). 176–185. 41 indexed citations
5.
Ruppe, Mary D., Xiao–Ping Zhang, Erik A. Imel, et al.. (2014). Assessment of Quality of Life Data After 4 Monthly S.C. Doses of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia. 82. 1 indexed citations
6.
Carpenter, Thomas O., Erik A. Imel, Mary D. Ruppe, et al.. (2014). Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. Journal of Clinical Investigation. 124(4). 1587–1597. 215 indexed citations
7.
Corwin, Howard L., Andrew Gettinger, Timothy C. Fabian, et al.. (2007). Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. New England Journal of Medicine. 357(10). 965–976. 360 indexed citations
8.
Blè, Alessandro, Jeffrey C. Fink, Richard C. Woodman, et al.. (2005). Renal Function, Erythropoietin, and Anemia of Older Persons. Archives of Internal Medicine. 165(19). 2222–2222. 90 indexed citations
9.
Germain, Michael J., et al.. (2005). Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrology Dialysis Transplantation. 20(10). 2146–2152. 27 indexed citations
10.
11.
Weatherby, Lisa B., et al.. (2001). Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘dear doctor’ letters. Pharmacoepidemiology and Drug Safety. 10(3). 211–218. 49 indexed citations
12.
Gupta, Suneel, et al.. (1999). Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. Journal of Pharmaceutical Sciences. 88(8). 835–841. 27 indexed citations
13.
Saag, Michael S., W. Jeffrey Fessel, Douglas Ward, et al.. (1999). Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis with Itraconazole Oral Solution in HIV-Positive Patients. AIDS Research and Human Retroviruses. 15(16). 1413–1417. 40 indexed citations
14.
Lange, David G., Joseph A. Guarnieri, R Savin, et al.. (1998). Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 39(6). 944–950. 32 indexed citations
15.
Gupta, Suneel, Mary Southam, Gayatri Sathyan, & Mark A. Klausner. (1998). Effect of Current Density on Pharmacokinetics Following Continuous or Intermittent Input from a Fentanyl Electrotransport System†. Journal of Pharmaceutical Sciences. 87(8). 976–981. 33 indexed citations
16.
Jeste, Dilip V., et al.. (1997). A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. Psychopharmacology. 131(3). 239–247. 22 indexed citations
17.
Lange, David G., et al.. (1997). Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers. The Journal of Clinical Pharmacology. 37(6). 535–540. 97 indexed citations
18.
Klausner, Mark A., Christopher Irwin, John F. Mullane, et al.. (1988). Effect of Cetamolol on Epinephrine‐Induced Hypokalemia. The Journal of Clinical Pharmacology. 28(8). 751–756. 3 indexed citations
19.
Klausner, Mark A., Daniel Ventura, J.B. Coelho, et al.. (1988). Cardioselectivity of Cetamolol Compared With Atenolol and Nadolol. The Journal of Clinical Pharmacology. 28(6). 495–504. 2 indexed citations
20.
Skoutakis, Vasilios A., et al.. (1988). Pharmacokinetics of Cetamolol in Hypertensive Patients with Normal and Compromised Renal Function. The Journal of Clinical Pharmacology. 28(5). 467–476. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara G. Delano Breakdown of academic impact, for papers by Benaya Rozen‐Zvi Breakdown of academic impact, for papers by W. Kline Bolton Breakdown of academic impact, for papers by Neil Boyce Breakdown of academic impact, for papers by Peter Rogiers Breakdown of academic impact, for papers by Carlos A. Vaamonde Breakdown of academic impact, for papers by Dierik Verbeelen Breakdown of academic impact, for papers by Sun-Hee Park Breakdown of academic impact, for papers by M. Elli Breakdown of academic impact, for papers by Ko‐Lin Kuo
Rankless by CCL
2026